Drugs for human or animal use may be considered to be in a special category of chemicals in the terms of potential impact on the environment. This is because the amount of a specific drug produced annually is relatively small, and prescription and animal drugs are used under controlled conditions. Perhaps a good example of this is the delivery systems where Freon is used as a propellant. This use probably should be continued since the amount of Freon used is a very small percentage of the total Freon used for all pbrposes. The benefit of the therapeutic use would outweigh the risk of environmental impact.
The biological activity of drugs is well known since they are studied extensively in animals and man prior to release for general use. Pharmacology studies in animals and man serve to determine the primary or desired biological activity including the mode of action ( Table 1) . Pharmacology studies also determine secondary activities which may not be desired and usually require larger doses than needed for the primary activity (Table 2) . Extensive toxicology and pathology studies, or safety assessment studies, in animals are used to detect potential adverse effects and to establish the margin of safety between exposure levels and toxic levels ( Table 3) . These studies are done in several species of animals and include acute, subacute or subchronic, chronic, and teratology and reproduction studies (Table 4) . Of most importance relative to safety are the subacute and chronic studies wherein doses ranging from near exposure levels to frankly toxic doses are used ( Table 5 ). Chronic studies include 3-. 6-. and 12-month experiments in at least two species of animals, one a nonrodent, and studies lasting 18 months in mice and/or 24 months in rats. In the teratology and reproduction studies the effect of the drug on organogenesis, male and female fertility, and on fetuses in late gestation and in pups up to or beyond weaning age, is determined (Table 6 ).
- Table 3 1. Determination of the type of adverse effect which can be elicited.
2. Exposure levels at which these adverse effects can be obtained. 3. The difference between the "toxic effect doses" and the therapeutic doses in the same species -margin of safety. Drugs which are to be used for long periods of time in man may be tested in all of the above toxicity experiments. Some drugs, such as antibiotics, wherein the duration of use will only be for a few days, may not be tested in animalsfor longer than three months unless the drug belongs to asuspect class of chemicals.
SAFETY ASSESSMENT -OBJECTIVES
Very potent carcinogens should be detected in threemonth studies while studies of 6 and 12 monthsshould reveal moderately potent carcinogens ( Table 7) . A careful review of all data, particularly of pathology studies, from these experiments should permit a good estimate of potential hazard for man and animals. .Metabolism studies in animals and man areoften extensive and can provide information of absorption, metabolism, tissue distribution, accumulation, and elimination (Table 8) .
As a general rule the metabolism of drugs is qualitatively similar in animals and man, and during the safety studies the animals would have been exposed to the metabolites. Occasionally it may be necessary to do at least some of the safety evaluation studies on a metabolite. This is particularly true if one of the metabolites is found to be unusally toxic, or.
to have a structure similar to that of a known carcinogen or teratogen. Also, if a metabolite is found to be specific for man, or the animal to receive the drug therapeutically, studies of this metabolite may be necessary.
Studies of drugs to be used in animals are similar to those used for human drugs. In addition, because of the "environmental" implications of tissue residues in food animals, additional studies of these residues may be necessary. Also, if an animal drug is to be given to groups of animals such as cattle, sheep, or pigs, it may be necessary tostudythe nature and environmental activity of the metabolites appearing in the excreta.
Since the use of a drug in man is generally limited to a relatively small portion of the population, the urinary content of the drugs or metabolites is diluted through the sewage disposal systems to such an extent that no risk to the environment is involved.
The manufacture of drugs requires various intermediates, and the byproducts of the synthetic procedures could enter the environment if not controlled. Therefore, the disposal of such agents must be controlled. At Merck, the manufacturing plants must meet the various standards for air and water quality for potential pollutants as established by the federal, state, and local authorities. The byproducts of synthesis which are not recoverable for reuse in manufacturing processes are disposed of along with waste materials from many other processes on a plant-wide basis. The waste liquors from all the manufacturing processes are blended, neutralized, and disposed of after they have been treated to meet the various environmental standards.
Any residues from the formulation of the final drug in the pharmaceutical manufacturing processes enter the general plant waste system which may include in-plant sewage wastes. This waste goes to an equalization tank which equalizes the flows discharged to the local sewage plant. Any solid wastes are combined with the general plant trash which is ground up and transferred to closed vehicles for disposal to approved landfills. All of these procedures are under the control of company engineers trained in the technique of waste treatment.
One other aspect of potential environmental impact is that of ransport of the bulk drug from the pointof manufactureto propriate capsules, tablets, injectables, and so forth. This transport may be within a plant site or it may be a distance of several hundred miles, or more.
It is interesting to note that in general the more potent an agent is pharmacologically or toxicologically, the smaller is the amount that may have to be transported to satisfy the therapeutic needs of the population. th d plant which formulates the final product into the apFor example, actinomycin, an anticancer drug with limited use, is very toxic, the parenteral LD 50 being in the order of 1 mg/kg for mice. Actinomycin is transported in quantities of about 300 grams for 90 miles about four times a year. B x a u s e of its toxicity it is transported in metal canisters.
Dexamethasone, an antiinflammatory steroid, has a parenteral LD,, of about 800 mg/kg, but oral doses of 1 mg/kg/day are toxic for animals because of its pharmacologic activity. The usual human dose for continued use is less than 3 mg/day. Dexamethasone is transported in 5-gallon metal pails about 90 miles from the point of manufacture to the point of formulation.
Methyldopa, which has avery low order of toxicity (animals tolerate 500 to 1000 mg/kg/day for several weeks without difficulty), requires rather large doses for therapy -500 to 2000 mg/day. Since it is widely used for the treatment of hypertension on a chronic basis, large amounts are needed to supply the therapeutic needs. A special plant is used for production in the United States. Methyldopa is delivered to the pharmaceutical plant from the factory over a distance of about 800 miles, two to three times a month, in fiber drums which hold 50 kilograms. True, i f an accident were to occur, the spill would probably be limited toa few drums and since it is relatively non-toxic, little if any damage to the environment would occur and the hazard to people or the environment would be negligible. I might add that over many years of transport there have been no spills due to accidents.
Thiabendazole is an interesting chemical which is used as an antihelmintic in man and animals and is also used as a fungicide in agriculture. Consequently, it has been studied extensively in animals and man and also for its effects on the environment. It has a low order of toxicity in all species studied.
With few exceptions, such as thiabendazole, drugs are not studied for their effects on the environment, i.e., birds, fishes, plants, since they are not intended to be used in such a way that there would be a significant impact on the environment.
Notwithstanding the above, the pharmaceutical companies do file an environmental impact analysis report* for each new drug. Comments are requested on the following points:
1. Describe the proposed action. 2. Discuss the probable impact of the action on the environment (including primary and secondary consequences).
3. Discuss the probable adverse environmental effects which cannot be avoided. 4. Evaluate alternatives to the proposed action. 5. Describe the relationship between local short-term uses of the environment with respect to the proposed action and the maintenance and enhancement of long-term productivity. 6. Describe any irreversible and irretrievable commitment of resources which would be involved in the proposed action should it be implemented. 7. Discuss the objection raised by other agencies, organizations, or individuals which are known to the applicant. 8. If the proposed action should be taken prior to 90 days from the circulation of a draft environmental impact statement, or 30 days from the filing of the final environmental impact statement, explain why. 9. Analyze whether the benefit to the public of the proposed action will outweigh the action's potential risk to the environment. The impact of drugs on the environment can be considered to be rather minimal because of the controlled manner in which most drugs are used. Although drugs sold over-thecounter are not controlled in a similar way, many of them have been used for long periods of time so their biological activity is well known or the amounts contained in the medication are so small that any potential impact on the environment would also be minimal. Perhaps aspirin is the most widely used over-the-counter drug.
As a rule the benefithisk evaluation of drugs would indicate that even though there might be some impact on the environment, this should be small, and it is probable that the benefits would outweigh the risk. 
